Last reviewed · How we verify
S-Ketamine 0.5
S-Ketamine is the active S-enantiomer of ketamine that acts as a non-competitive antagonist at the NMDA receptor, blocking glutamate signaling in the central nervous system.
S-Ketamine is the active S-enantiomer of ketamine that acts as a non-competitive antagonist at the NMDA receptor, blocking glutamate signaling in the central nervous system. Used for General anesthesia induction and maintenance, Analgesia and sedation.
At a glance
| Generic name | S-Ketamine 0.5 |
|---|---|
| Also known as | Ketanest-S, Jiangsu Hengrui Medicine Co.,Ltd. |
| Sponsor | Turku University Hospital |
| Drug class | NMDA receptor antagonist |
| Target | NMDA receptor |
| Modality | Small molecule |
| Therapeutic area | Anesthesia; Psychiatry |
| Phase | FDA-approved |
Mechanism of action
S-Ketamine preferentially blocks NMDA receptors compared to the R-enantiomer, leading to rapid dissociative and anesthetic effects. It is used clinically for anesthesia induction and maintenance, and has been investigated for rapid-acting antidepressant effects through modulation of glutamatergic neurotransmission.
Approved indications
- General anesthesia induction and maintenance
- Analgesia and sedation
Common side effects
- Dissociation
- Dizziness
- Nausea
- Increased blood pressure
- Tachycardia
Key clinical trials
- Esketamine-propofol Versus Propofol for Flexible Bronchoscopy (PHASE4)
- Effects of Ketamine in the Acute Phase of Suicidal Ideation (PHASE3)
- Efficacy of Propofol-Ketamine and Sevoflurane in Children Undergoing Magnetic Resonance Imaging (NA)
- Non-opioid Anesthesia Based on Thoracic Paravertebral Block During Laparoscopic Sleeve Gastrectomy (NA)
- Efficacy of Esketamine Combined With Different General Anesthetics on Quality of Postoperative Recovery (NA)
- A General Anesthesia Regimen for DBS Surgery in Patients With PD (NA)
- Initiating Ketamine in Acutely Suicidal Patients in the Emergency Department (PHASE3)
- Ketamine Safety and Tolerability in Psychiatric Inpatient Care (KetGD)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- S-Ketamine 0.5 CI brief — competitive landscape report
- S-Ketamine 0.5 updates RSS · CI watch RSS
- Turku University Hospital portfolio CI